IRVINE, Calif.--(BUSINESS WIRE)--May 9, 2017--
(NASDAQ:MASI) today announced the introduction of Rad-G™, a combined
pulse oximeter designed primarily for use in pneumonia screening and
spot-checking of oxygen saturation (SpO2) in low-resource
settings. The development of the device is supported in part by a grant
of $4.95 million from the Bill & Melinda Gates Foundation (BMGF),
announced in November 2016, as part of a partnership with Masimo to
facilitate screening for pneumonia by health workers in low-resource
This Smart News Release features multimedia. View the full release here:
Masimo Rad-G™ Pulse Oximeter (Photo: Business Wire)
Rad-G is a low-cost, rugged, handheld pulse oximetry device with a
rechargeable battery and LCD display. It uses Masimo Measure-through
Motion and Low Perfusion™ SET® pulse oximetry technology to
measure SpO2, respiration rate from the Pleth (RRp™), pulse
rate (PR), and perfusion index (Pi).
Pneumonia remains the single largest treatable infectious cause of death
in children worldwide, causing over 900,000 deaths each year among
children under 5 years of age.1 In a study funded by the BMGF
Diagnostics Modelling Consortium, the researchers concluded that in
settings where supplemental oxygen is available, the addition of pulse
oximetry to standard integrated management of child illness protocols
could reduce pneumonia mortality rates.2 More recently, the
World Health Organization (WHO) has been conducting a multi-country
evaluation of enhanced community case management of pneumonia with the
use of Masimo SET® pulse oximetry by community health workers.3
Enhancing patient screening is critically important to reducing the
global burden of pneumonia. Moreover, enhanced screening may empower
healthcare providers by supporting informed decisions related to
pneumonia diagnosis and treatment, with the appropriate administration
of antibiotics and oxygen therapy when needed. Masimo and BMGF hope that
Masimo pulse oximetry technology, already used to monitor approximately
100 million patients around the world, can help better screen children
in even the most challenging conditions.
Joe Kiani, Founder and CEO of Masimo, said, “The introduction of the
Rad-G is a critical milestone in our partnership with the Bill & Melinda
Gates Foundation to help improve pneumonia screening. We are grateful to
have the opportunity to bring our proven SET® pulse oximetry
technology to areas of the world that are in desperate need of better
healthcare, and look forward to making a positive difference in the
lives of many children.”
Rad-G is currently not available for sale in the United States, Canada,
or the E.U.
Pneumonia Fact Sheet, World Health Organization (WHO), September 2016.
Floyd J et al. Evaluating the impact of pulse oximetry on childhood
pneumonia mortality in resource-poor settings. Nature. 2015 Dec
- World Health Organization (WHO), 2016.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 including 17 of the top 20 hospitals listed in the
2016-17 U.S. News and World Report Best Hospitals Honor Roll.7
In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
and more recently, Pleth Variability Index (PVi®) and Oxygen
Reserve Index (ORi™), in addition to SpO2, pulse rate, and
perfusion index (PI). In 2014, Masimo introduced Root®, an
intuitive patient monitoring and connectivity platform with the Masimo
Open Connect™ (MOC-9™) interface, enabling other companies to augment
Root with new features and measurement capabilities. Masimo is also
taking an active leadership role in mHealth with products such as the
Radius-7™ wearable patient monitor, iSpO2® pulse
oximeter for smartphones, and the MightySat™ fingertip pulse oximeter.
Additional information about Masimo and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
Estimate: Masimo data on file.
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Rad-G™.These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo Rad-G, contribute to positive clinical
outcomes and patient safety; as well as other factors discussed in the
"Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170509005646/en/
Evan Lamb, 949-396-3376